Search Results
Adam Brufsky, MD, PhD: Choices of Therapy in Breast Cancer
Adam Brufsky, MD, PhD: Clinical Trial Data Supporting These Choices
Adam Brufsky, MD, PhD, considers the investigation of poziotinib in HER2+ metastatic breast cancer
Dr. Brufsky on the COLET Trial for Triple-Negative Breast Cancer
Dr. Brufsky on Biosimilars Being Explored in Oncology
Choosing Therapy for HR+ Metastatic Breast Cancer
Practice-Changing Results from the MINDACT Trial
Adjuvant Therapy for Breast Cancer
Neoadjuvant T-DM1 in HER2+ Early Breast Cancer
Final Thoughts on Advanced Breast Cancer
Biosimilar Interchangeability in Practice
CDK4/6 Inhibitors for HR+ Metastatic Breast Cancer